AAT + Placebo
Phase 2/3Active 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute-graft-versus-host Disease
Conditions
Acute-graft-versus-host Disease
Trial Timeline
Mar 27, 2019 → Mar 31, 2026
NCT ID
NCT03805789About AAT + Placebo
AAT + Placebo is a phase 2/3 stage product being developed by CSL for Acute-graft-versus-host Disease. The current trial status is active. This product is registered under clinical trial identifier NCT03805789. Target conditions include Acute-graft-versus-host Disease.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03805789 | Phase 2/3 | Active |
Competing Products
2 competing products in Acute-graft-versus-host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| Glassia | Kamada | Pre-clinical | 15 |